Latest / Vertical SaaS with Fexingo: Industry-Specific Software for Healthcare, Construction, Legal / How Veeva Systems Won Pharma by Solving One Data Problem
Transcript
- Lucas: There is a company called Veeva Systems that generates over two and a half billion dollars in annual revenue, and roughly ninety-nine percent of its customers are pharmaceutical and life sciences companies. Not healthcare broadly — specifically pharma. And the interesting part is, for its first decade, it ran on top of Salesforce's platform. Luna: Wait — so Veeva was basically a Salesforce add-on for pharma? Lucas: That's exactly how it started. Peter Gassner, the founder, had been a Salesforce executive. He saw that pharma companies had very specific needs — managing doctor relationships, tracking samples, handling regulatory submissions — and Salesforce's generic CRM wasn't cutting it. So he built Veeva as what's called a 'platform application' on Force.com, Salesforce's development environment. Luna: And Salesforce was okay with that? They basically incubated a competitor. Lucas: For a long time, yes. Salesforce was happy to collect the platform fees. Veeva paid them a cut of revenue. But by 2021, Gassner decided Veeva had to own its own technology stack. He announced they were migrating off Salesforce onto their own cloud infrastructure. It was a multiyear, hundreds of millions of dollars project. Luna: That's a huge bet. Why take that risk when the existing setup was working? Lucas: Two reasons. First, margin. Veeva was paying Salesforce roughly seven percent of revenue as platform fees. That's about one hundred and seventy-five million dollars a year. If they own the infrastructure, that money goes to their own bottom line. Second, product control. They wanted to build features that Salesforce's platform couldn't support easily, like their own content management system for regulatory documents. Luna: So they went from being a tenant to being the landlord. Lucas: Exactly. And the market rewarded them. Veeva's stock — ticker symbol V-E-E-V — has performed well through that transition. Analysts focus on their net dollar retention rate, which has consistently been above one hundred and twenty percent. That means existing customers are spending over twenty percent more each year, even before adding new logos. Luna: That's incredible. Most SaaS companies aim for one hundred and ten or one hundred and fifteen. One twenty is best-in-class. Lucas: Right. And it makes sense when you think about the vertical. A pharmaceutical company launching a new drug needs to train sales reps, create compliant marketing materials, track every interaction with doctors — that's a growing workload every year. Veeva's platform becomes more embedded. They now offer cloud applications for clinical trials, regulatory submissions, quality management. It's a suite. Luna: So competitors haven't been able to break in? Lucas: There are niche players — companies like IQVIA in clinical data, or Oracle's Health Sciences unit. But no one has built the comprehensive platform Veeva has for pharma specifically. And switching costs are enormous. If you're a top-twenty pharma company, you have thousands of users trained on Veeva, years of data in their systems, regulatory workflows baked into the software. You don't rip that out for a small price difference. Luna: It's the classic vertical SaaS moat — deep integration into a specific industry's workflow. Lucas: Precisely. And Veeva's numbers bear that out. As of early 2026, they serve over one thousand four hundred customers, including all of the top twenty global pharma companies. Their revenue growth has been around fifteen to twenty percent annually, even as the overall SaaS market slowed. Operating margins are over thirty percent. Luna: That's better than most horizontal SaaS companies. Salesforce itself has operating margins in the high teens. Lucas: Right. And that's the vertical SaaS thesis in a nutshell: if you pick a sticky, regulated industry, you can charge premium prices, keep customers for a decade or more, and generate cash flow that horizontal players envy. The trade-off is that your total addressable market is smaller. Veeva's TAM is maybe fifteen to twenty billion dollars — huge for a single company, but tiny compared to Salesforce's hundred billion plus opportunity. Luna: But the growth comes from expanding within each customer, not from chasing new verticals. Lucas: Exactly. Veeva doesn't try to sell to banks or retailers. They stay in their lane. And that discipline is part of why they've been so profitable. Gassner has said publicly that they consider vertical focus a competitive advantage, not a limitation. Luna: I want to go back to the migration off Salesforce. How did that actually play out? Was it disruptive? Lucas: It was a massive engineering effort. They started in 2021, built their own cloud infrastructure on Amazon Web Services, and migrated over five hundred applications. They finished in late 2024. During the transition, they maintained both platforms simultaneously, which added cost. But by 2025, they were fully on their own stack, and the margin improvement started showing. Luna: And customers didn't churn during that period? Lucas: Net dollar retention actually stayed above one hundred twenty percent. That tells you customers were satisfied enough to expand their spend even while the platform was being rebuilt under them. That's a testament to the relationship Veeva has with its customers. Luna: It's also a testament to the stickiness of regulatory software. You can't just pause compliance workflows. Lucas: Exactly. And that's the lesson for anyone evaluating vertical SaaS businesses. Look for industries where software is tied to a legal or regulatory requirement. In pharma, if you don't track every sample you give a doctor, you can get fined by the Department of Justice. That's a much stronger buying motive than 'we want to improve sales efficiency.' Luna: So the moat isn't just technical — it's legal and operational. Lucas: Yes. And that's why Veeva can charge premium prices. Their average revenue per customer is over one point eight million dollars annually. For the largest pharma companies, it's in the tens of millions. And those customers rarely leave. Luna: I'm curious about the founder. Peter Gassner — what's his background? Lucas: He was a senior vice president at Salesforce, leading their platform business. He saw the pharma opportunity firsthand because Salesforce's own CRM wasn't meeting those needs. So he left in 2007 to start Veeva with a clear vision: build the industry cloud for life sciences. He's still CEO today. That's unusual for a company that's been public since 2013. Luna: Founder-led, long-term focused. That probably helps with the discipline to stay vertical. Lucas: Absolutely. Gassner has said he's not interested in entering adjacent verticals like healthcare providers or insurance. He thinks the life sciences vertical is deep enough to keep Veeva busy for decades. And the numbers support that — they still have plenty of room to grow within pharma, especially in emerging markets and in newer areas like regulatory submission management. Luna: Is there a risk that Salesforce or Oracle builds a competing product specifically for pharma? Lucas: They've tried. Salesforce launched Health Cloud, but it's more focused on provider and payer relationships, not the full pharma workflow. Oracle has their own life sciences unit, but it's fragmented across acquisitions. The challenge is that building a vertical product requires deep domain expertise — you need to understand clinical trials, pharmacovigilance, regulatory filings. That's not something a horizontal platform can easily replicate. Luna: So Veeva's head start is essentially unassailable. Lucas: In the near term, yes. The combination of domain expertise, embedded workflows, and high switching costs creates a very defensible position. And because they're generating strong free cash flow, they can invest in R&D at a level that keeps them ahead. Luna: What about the broader vertical SaaS landscape? Are there other companies following a similar playbook? Lucas: Many. We've talked on this show about Epic in healthcare, Procore in construction, Clio in legal. Each of those companies dominates a vertical by building deep, industry-specific functionality that horizontal players can't match. Veeva is arguably the purest example because their entire revenue comes from one vertical and they've maintained best-in-class financial metrics. Luna: And the market has rewarded them. Veeva's market cap is around thirty-five billion dollars, which is about fourteen times revenue. That's a premium multiple, reflecting that sticky growth. Lucas: Exactly. For investors, vertical SaaS companies with high net dollar retention and operating margins above thirty percent are rare. Veeva checks both boxes. The question is whether they can sustain growth as they approach market saturation in the largest pharma companies. Luna: What's their next growth vector? Lucas: They're expanding into what they call 'Vault' — a content management platform for regulatory documents. That's a huge market because every drug submission requires thousands of pages of documentation. They're also moving into clinical trial management, which is currently dominated by older players like Medidata. And they're growing internationally — their revenue outside the U.S. is still a relatively small portion of total revenue. Luna: So there's a long runway. But it requires maintaining that vertical focus. Lucas: Right. And that's the tension every successful vertical SaaS company faces. As you get bigger, there's pressure to broaden your market to keep growth rates up. Some companies resist — Veeva seems to be one. Others give in and start chasing horizontal expansion, often with mixed results. Luna: So the lesson from Veeva is: pick a deep vertical, build for regulation, and don't get distracted. Lucas: That's the playbook. And it's a reminder that in software, sometimes the most profitable businesses aren't the ones trying to serve everyone — they're the ones that serve a specific industry better than anyone else.